{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:12:43Z","timestamp":1790975563066,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-58669-7","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:44:07Z","timestamp":1746521047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A potent protective bispecific nanobody targeting Herpes simplex virus gD reveals vulnerable epitope for neutralizing"],"prefix":"10.1038","volume":"16","author":[{"given":"Jing","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6289-2910","authenticated-orcid":false,"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanwen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaolu","family":"Hasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-6242","authenticated-orcid":false,"given":"Dongli","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-1307","authenticated-orcid":false,"given":"Chenghao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-0869","authenticated-orcid":false,"given":"Shu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1395-188X","authenticated-orcid":false,"given":"Tengchuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"58669_CR1","doi-asserted-by":"crossref","unstructured":"Piret, J. & Boivin, G. Immunomodulatory strategies in herpes simplex virus encephalitis. Clin. Microbiol. Rev. 33, e00105-19 (2020).","DOI":"10.1128\/CMR.00105-19"},{"key":"58669_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.preteyeres.2012.08.002","volume":"32","author":"AM Rowe","year":"2013","unstructured":"Rowe, A. M. et al. Herpes keratitis. Prog. Retinal Eye Res. 32, 88\u2013101 (2013).","journal-title":"Prog. Retinal Eye Res."},{"key":"58669_CR3","doi-asserted-by":"publisher","first-page":"724618","DOI":"10.3389\/fimmu.2021.724618","volume":"12","author":"E Feng","year":"2021","unstructured":"Feng, E., Balint, E., Vahedi, F. & Ashkar, A. A. Immunoregulatory functions of interferons during genital HSV-2 infection. Front Immunol. 12, 724618 (2021).","journal-title":"Front Immunol."},{"key":"58669_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1600-0714.2007.00586.x","volume":"37","author":"PG Arduino","year":"2008","unstructured":"Arduino, P. G. & Porter, S. R. Herpes simplex virus type 1 infection: overview on relevant clinico-pathological features*. J. Oral. Pathol. Med. 37, 107\u2013121 (2008).","journal-title":"J. Oral. Pathol. Med."},{"key":"58669_CR5","doi-asserted-by":"publisher","first-page":"e1008899","DOI":"10.1371\/journal.ppat.1008899","volume":"16","author":"H Qiao","year":"2020","unstructured":"Qiao, H. et al. Herpes simplex virus type 1 infection leads to neurodevelopmental disorder-associated neuropathological changes. PLOS Pathog. 16, e1008899 (2020).","journal-title":"PLOS Pathog."},{"key":"58669_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2471\/BLT.19.237149","volume":"98","author":"C James","year":"2020","unstructured":"James, C. et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull. World Health Organ 98, 315\u2013329 (2020).","journal-title":"Bull. World Health Organ"},{"key":"58669_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jpeds.2013.02.004","volume":"163","author":"EJ Williams","year":"2013","unstructured":"Williams, E. J. et al. Viral infections: contributions to late fetal death, stillbirth, and infant death. J. Pediatrics 163, 424\u2013428 (2013).","journal-title":"J. Pediatrics"},{"key":"58669_CR8","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/OLQ.0000000000001458","volume":"48","author":"JS Slutsker","year":"2021","unstructured":"Slutsker, J. S. & Schillinger, J. A. Assessing the burden of infant deaths due to herpes simplex virus, human immunodeficiency virus, and congenital syphilis: united states, 1995 to 2017. Sex. Transm. Dis. 48, S4\u2013s10 (2021).","journal-title":"Sex. Transm. Dis."},{"key":"58669_CR9","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1016\/j.vaccine.2017.09.044","volume":"37","author":"JT Schiffer","year":"2019","unstructured":"Schiffer, J. T. & Gottlieb, S. L. Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development. Vaccine 37, 7363\u20137371 (2019).","journal-title":"Vaccine"},{"key":"58669_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-016-0887-y","volume":"16","author":"K Aebi-Popp","year":"2016","unstructured":"Aebi-Popp, K., Bailey, H., Malyuta, R., Volokha, A. & Thorne, C. High prevalence of herpes simplex virus (HSV)- type 2 co-infection among HIV-positive women in Ukraine, but no increased HIV mother-to-child transmission risk. BMC Pregnancy Childbirth 16, 94 (2016).","journal-title":"BMC Pregnancy Childbirth"},{"key":"58669_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/v15020439","volume":"15","author":"R Tayyar","year":"2023","unstructured":"Tayyar, R. & Ho, D. Herpes simplex virus and varicella zoster virus infections in cancer patients. Viruses 15, 439 (2023).","journal-title":"Viruses"},{"key":"58669_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev-virology-092917-043457","volume":"5","author":"CL Poole","year":"2018","unstructured":"Poole, C. L. & Kimberlin, D. W. Antiviral approaches for the treatment of herpes simplex virus infections in newborn infants. Annu Rev. Virol. 5, 407\u2013425 (2018).","journal-title":"Annu Rev. Virol."},{"key":"58669_CR13","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa1003509","volume":"365","author":"W Kimberlin David","year":"2004","unstructured":"Kimberlin David, W. et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N. Engl. J. Med. 365, 1284\u20131292 (2004).","journal-title":"N. Engl. J. Med."},{"key":"58669_CR14","doi-asserted-by":"publisher","first-page":"115322","DOI":"10.1016\/j.bcp.2022.115322","volume":"206","author":"HH Schalkwijk","year":"2022","unstructured":"Schalkwijk, H. H., Snoeck, R. & Andrei, G. Acyclovir resistance in herpes simplex viruses: prevalence and therapeutic alternatives. Biochem. Pharmacol. 206, 115322 (2022).","journal-title":"Biochem. Pharmacol."},{"key":"58669_CR15","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.2174\/0929867325666180309105519","volume":"27","author":"K K\u0142ysik","year":"2020","unstructured":"K\u0142ysik, K., Pietraszek, A., Karewicz, A. & Nowakowska, M. Acyclovir in the treatment of herpes viruses\u2014a review. Curr. Med. Chem. 27, 4118\u20134137 (2020).","journal-title":"Curr. Med. Chem."},{"key":"58669_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1006\/viro.1996.0011","volume":"215","author":"PP Sanna","year":"1996","unstructured":"Sanna, P. P. et al. Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Virology 215, 101\u2013106 (1996).","journal-title":"Virology"},{"key":"58669_CR17","doi-asserted-by":"crossref","unstructured":"Wang, K. et al. Monoclonal antibodies, derived from humans vaccinated with the RV144 HIV vaccine containing the HVEM binding domain of herpes simplex virus (HSV) glycoprotein D, neutralize HSV infection, mediate antibody-dependent cellular cytotoxicity, and protect mice from ocular challenge with HSV-1. J. Virol. 91, e00411-17 (2017).","DOI":"10.1128\/JVI.00411-17"},{"key":"58669_CR18","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1107\/S0907444913016776","volume":"69","author":"C-C Lee","year":"2013","unstructured":"Lee, C.-C. et al. Structural basis for the antibody neutralization of Herpes simplex virus. Acta Crystallogr. Sect. D. 69, 1935\u20131945 (2013).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"58669_CR19","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1073\/pnas.1220019110","volume":"110","author":"A Krawczyk","year":"2013","unstructured":"Krawczyk, A. et al. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc. Natl Acad. Sci. USA 110, 6760\u20136765 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"58669_CR20","doi-asserted-by":"crossref","unstructured":"Cairns Tina, M. et al. Localization of the interaction site of herpes simplex virus glycoprotein D (gD) on the membrane fusion regulator, gH\/gL. J. Virol. 94, e00983-20 (2020).","DOI":"10.1128\/JVI.00983-20"},{"key":"58669_CR21","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3389\/fimmu.2017.01802","volume":"8","author":"Y Wu","year":"2017","unstructured":"Wu, Y., Jiang, S. & Ying, T. Single-domain antibodies as therapeutics against human viral diseases. Front Immunol. 8, 1802 (2017).","journal-title":"Front Immunol."},{"key":"58669_CR22","first-page":"59","volume":"12","author":"F Fotouhi","year":"2008","unstructured":"Fotouhi, F., Soleimanjahi, H., Roostaee, M. H. & Dalimi Asl, A. Expression of the herpes simplex virus type 2 glycoprotein D in baculovirus expression system and evaluation of its immunogenicity in guinea pigs. Iran. Biomed. J. 12, 59\u201366 (2008).","journal-title":"Iran. Biomed. J."},{"key":"58669_CR23","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1128\/JVI.03163-13","volume":"88","author":"S Awasthi","year":"2014","unstructured":"Awasthi, S. et al. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs. J. Virol. 88, 2000\u20132010 (2014).","journal-title":"J. Virol."},{"key":"58669_CR24","doi-asserted-by":"publisher","first-page":"e1011804","DOI":"10.1371\/journal.ppat.1011804","volume":"19","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization. PLOS Pathog. 19, e1011804 (2023).","journal-title":"PLOS Pathog."},{"key":"58669_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tibtech.2014.03.001","volume":"32","author":"T De Meyer","year":"2014","unstructured":"De Meyer, T., Muyldermans, S. & Depicker, A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol. 32, 263\u2013270 (2014).","journal-title":"Trends Biotechnol."},{"key":"58669_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41421-022-00497-w","volume":"8","author":"H Ma","year":"2022","unstructured":"Ma, H. et al. A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration. Cell Discov. 8, 132 (2022).","journal-title":"Cell Discov."},{"key":"58669_CR27","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/s41422-022-00700-3","volume":"32","author":"H Ma","year":"2022","unstructured":"Ma, H. et al. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron. Cell Res. 32, 831\u2013842 (2022).","journal-title":"Cell Res."},{"key":"58669_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1097-2765(01)00298-2","volume":"8","author":"A Carf\u00ed","year":"2001","unstructured":"Carf\u00ed, A. et al. Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol. Cell 8, 169\u2013179 (2001).","journal-title":"Mol. Cell"},{"key":"58669_CR29","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1128\/JVI.79.2.1282-1295.2005","volume":"79","author":"SA Connolly","year":"2005","unstructured":"Connolly, S. A. et al. Potential nectin-1 binding site on herpes simplex virus glycoprotein D. J. Virol. 79, 1282\u20131295 (2005).","journal-title":"J. Virol."},{"key":"58669_CR30","doi-asserted-by":"publisher","first-page":"e1002277","DOI":"10.1371\/journal.ppat.1002277","volume":"7","author":"P Di Giovine","year":"2011","unstructured":"Di Giovine, P. et al. Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLOS Pathog. 7, e1002277 (2011).","journal-title":"PLOS Pathog."},{"key":"58669_CR31","doi-asserted-by":"publisher","first-page":"13678","DOI":"10.1128\/JVI.01906-14","volume":"88","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. Crystal structure of herpes simplex virus 2 gD bound to nectin-1 reveals a conserved mode of receptor recognition. J. Virol. 88, 13678\u201313688 (2014).","journal-title":"J. Virol."},{"key":"58669_CR32","doi-asserted-by":"publisher","first-page":"12292","DOI":"10.1128\/JVI.01700-10","volume":"84","author":"D Atanasiu","year":"2010","unstructured":"Atanasiu, D., Saw, W. T., Cohen, G. H. & Eisenberg, R. J. Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH\/gL, and gB. J. Virol. 84, 12292\u201312299 (2010).","journal-title":"J. Virol."},{"key":"58669_CR33","doi-asserted-by":"crossref","unstructured":"Fontana, J. et al. The fusion loops of the initial prefusion conformation of herpes simplex virus 1 fusion protein point toward the membrane. mBio 8, e01268-17 (2017).","DOI":"10.1128\/mBio.01268-17"},{"key":"58669_CR34","doi-asserted-by":"crossref","unstructured":"Atanasiu, D. et al. Using antibodies and mutants to localize the presumptive gH\/gL binding site on herpes simplex virus gD. J. Virol. 92, e01694-18 (2018).","DOI":"10.1128\/JVI.01694-18"},{"key":"58669_CR35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220110","volume":"219","author":"IM Backes","year":"2022","unstructured":"Backes, I. M. et al. Maternally transferred mAbs protect neonatal mice from HSV-induced mortality and morbidity. J. Exp. Med. 219, e20220110 (2022).","journal-title":"J. Exp. Med."},{"key":"58669_CR36","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nrmicro1972","volume":"6","author":"Q Sattentau","year":"2008","unstructured":"Sattentau, Q. Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev. Microbiol. 6, 815\u2013826 (2008).","journal-title":"Nat. Rev. Microbiol."},{"key":"58669_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.virol.2021.01.016","volume":"556","author":"S Wang","year":"2021","unstructured":"Wang, S., Hou, F., Yao, Y. F. & Pan, D. Efficient establishment of reactivatable latency by an acyclovir-resistant herpes simplex virus 1 thymidine kinase substitution mutant with reduced neuronal replication. Virology 556, 140\u2013148 (2021).","journal-title":"Virology"},{"key":"58669_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105298","volume":"201","author":"R Tian","year":"2022","unstructured":"Tian, R. et al. A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D. Antivir. Res. 201, 105298 (2022).","journal-title":"Antivir. Res."},{"key":"58669_CR39","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1128\/JVI.01924-10","volume":"85","author":"A Krawczyk","year":"2011","unstructured":"Krawczyk, A. et al. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J. Virol. 85, 1793\u20131803 (2011).","journal-title":"J. Virol."},{"key":"58669_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1073\/pnas.91.1.355","volume":"91","author":"R Burioni","year":"1994","unstructured":"Burioni, R., Williamson, R. A., Sanna, P. P., Bloom, F. E. & Burton, D. R. Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro. Proc. Natl Acad. Sci. USA 91, 355\u2013359 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"58669_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12929-024-01045-2","volume":"31","author":"N Seyfizadeh","year":"2024","unstructured":"Seyfizadeh, N. et al. Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus. J. Biomed. Sci. 31, 56 (2024).","journal-title":"J. Biomed. Sci."},{"key":"58669_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/jmv.1890390302","volume":"39","author":"E Aurelius","year":"1993","unstructured":"Aurelius, E., Johansson, B., Sk\u00f6ldenberg, B. & Forsgren, M. Encephalitis in immunocompetent patients due to herpes simplex virus type 1 or 2 as determined by type-specific polymerase chain reaction and antibody assays of cerebrospinal fluid. J. Med Virol. 39, 179\u2013186 (1993).","journal-title":"J. Med Virol."},{"key":"58669_CR43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1086\/341405","volume":"35","author":"F Raschilas","year":"2002","unstructured":"Raschilas, F. et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin. Infect. Dis. 35, 254\u2013260 (2002).","journal-title":"Clin. Infect. Dis."},{"key":"58669_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-1046-y","volume":"19","author":"Y Jouan","year":"2015","unstructured":"Jouan, Y. et al. Long-term outcome of severe herpes simplex encephalitis: a population-based observational study. Crit. Care 19, 345 (2015).","journal-title":"Crit. Care"},{"key":"58669_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/COH.0b013e328322f94a","volume":"4","author":"N Martin","year":"2009","unstructured":"Martin, N. & Sattentau, Q. Cell-to-cell HIV-1 spread and its implications for immune evasion. Curr. Opin. HIV AIDS 4, 143\u2013149 (2009).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"58669_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.coviro.2012.12.002","volume":"3","author":"TJ Henrich","year":"2013","unstructured":"Henrich, T. J. & Kuritzkes, D. R. HIV-1 entry inhibitors: recent development and clinical use. Curr. Opin. Virol. 3, 51\u201357 (2013).","journal-title":"Curr. Opin. Virol."},{"key":"58669_CR47","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.antiviral.2008.03.004","volume":"79","author":"H Jenssen","year":"2008","unstructured":"Jenssen, H., Sandvik, K., Andersen, J. H., Hancock, R. E. & Gutteberg, T. J. Inhibition of HSV cell-to-cell spread by lactoferrin and lactoferricin. Antivir. Res 79, 192\u2013198 (2008).","journal-title":"Antivir. Res"},{"key":"58669_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. Sect. D. 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"58669_CR49","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl Crystallogr 40, 658\u2013674 (2007).","journal-title":"J. Appl Crystallogr"},{"key":"58669_CR50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"58669_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13365-014-0302-2","volume":"21","author":"CM Kollias","year":"2015","unstructured":"Kollias, C. M., Huneke, R. B., Wigdahl, B. & Jennings, S. R. Animal models of herpes simplex virus immunity and pathogenesis. J. NeuroVirol. 21, 8\u201323 (2015).","journal-title":"J. NeuroVirol."},{"key":"58669_CR52","first-page":"2147","volume":"11","author":"R Ce\u00f1a-Diez","year":"2016","unstructured":"Ce\u00f1a-Diez, R. et al. Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action. Int J. Nanomed. 11, 2147\u20132162 (2016).","journal-title":"Int J. Nanomed."},{"key":"58669_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.antiviral.2017.10.013","volume":"147","author":"R Du","year":"2017","unstructured":"Du, R. et al. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus. Antivir. Res. 147, 131\u2013141 (2017).","journal-title":"Antivir. Res."},{"key":"58669_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-016-0508-4","volume":"13","author":"Y Luo","year":"2016","unstructured":"Luo, Y. et al. Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera. Virol. J. 13, 44 (2016).","journal-title":"Virol. J."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58669-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T09:03:30Z","timestamp":1746522210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58669-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58669"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58669-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"18 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4196"}}